229 related articles for article (PubMed ID: 24122209)
1. Mouse tumour models to guide drug development and identify resistance mechanisms.
Das Thakur M; Pryer NK; Singh M
J Pathol; 2014 Jan; 232(2):103-11. PubMed ID: 24122209
[TBL] [Abstract][Full Text] [Related]
2. The mighty mouse: genetically engineered mouse models in cancer drug development.
Sharpless NE; Depinho RA
Nat Rev Drug Discov; 2006 Sep; 5(9):741-54. PubMed ID: 16915232
[TBL] [Abstract][Full Text] [Related]
3. From mice to men: GEMMs as trial patients for new NSCLC therapies.
Hayes SA; Hudson AL; Clarke SJ; Molloy MP; Howell VM
Semin Cell Dev Biol; 2014 Mar; 27():118-27. PubMed ID: 24718320
[TBL] [Abstract][Full Text] [Related]
4. The challenge of selecting the 'right' in vivo oncology pharmacology model.
Firestone B
Curr Opin Pharmacol; 2010 Aug; 10(4):391-6. PubMed ID: 20634135
[TBL] [Abstract][Full Text] [Related]
5. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
6. New models for cancer research: human cancer stem cell xenografts.
Baiocchi M; Biffoni M; Ricci-Vitiani L; Pilozzi E; De Maria R
Curr Opin Pharmacol; 2010 Aug; 10(4):380-4. PubMed ID: 20561817
[TBL] [Abstract][Full Text] [Related]
7. A minimal model of tumor growth inhibition in combination regimens under the hypothesis of no interaction between drugs.
Magni P; Terranova N; Del Bene F; Germani M; De Nicolao G
IEEE Trans Biomed Eng; 2012 Aug; 59(8):2161-70. PubMed ID: 22575633
[TBL] [Abstract][Full Text] [Related]
8. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.
Ruggeri BA; Camp F; Miknyoczki S
Biochem Pharmacol; 2014 Jan; 87(1):150-61. PubMed ID: 23817077
[TBL] [Abstract][Full Text] [Related]
9. Patient-derived tumour xenografts as models for breast cancer drug development.
Marangoni E; Poupon MF
Curr Opin Oncol; 2014 Nov; 26(6):556-61. PubMed ID: 25188472
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response.
Wong H; Choo EF; Alicke B; Ding X; La H; McNamara E; Theil FP; Tibbitts J; Friedman LS; Hop CE; Gould SE
Clin Cancer Res; 2012 Jul; 18(14):3846-55. PubMed ID: 22648270
[TBL] [Abstract][Full Text] [Related]
11. Modeling therapy resistance in genetically engineered mouse cancer models.
Rottenberg S; Jonkers J
Drug Resist Updat; 2008; 11(1-2):51-60. PubMed ID: 18165147
[TBL] [Abstract][Full Text] [Related]
12. A mathematical model to study the effects of drugs administration on tumor growth dynamics.
Magni P; Simeoni M; Poggesi I; Rocchetti M; De Nicolao G
Math Biosci; 2006 Apr; 200(2):127-51. PubMed ID: 16516246
[TBL] [Abstract][Full Text] [Related]
13. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
15. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology.
Mazur PK; Siveke JT
Gut; 2012 Oct; 61(10):1488-500. PubMed ID: 21873467
[TBL] [Abstract][Full Text] [Related]
16. Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation.
Wartha K; Herting F; Hasmann M
Pharmacol Ther; 2014 Jun; 142(3):351-61. PubMed ID: 24412280
[TBL] [Abstract][Full Text] [Related]
17. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology.
Rosfjord E; Lucas J; Li G; Gerber HP
Biochem Pharmacol; 2014 Sep; 91(2):135-43. PubMed ID: 24950467
[TBL] [Abstract][Full Text] [Related]
18. Mathematical modeling of tumor growth, drug-resistance, toxicity, and optimal therapy design.
Hadjiandreou MM; Mitsis GD
IEEE Trans Biomed Eng; 2014 Feb; 61(2):415-25. PubMed ID: 24021634
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling.
Frederiksen LJ; Sullivan R; Maxwell LR; Macdonald-Goodfellow SK; Adams MA; Bennett BM; Siemens DR; Graham CH
Clin Cancer Res; 2007 Apr; 13(7):2199-206. PubMed ID: 17404104
[TBL] [Abstract][Full Text] [Related]
20. Strategies to translate preclinical information to breast cancer patient benefit.
Daidone MG; Zaffaroni N; Cappelletti V
J Natl Cancer Inst Monogr; 2011; 2011(43):55-9. PubMed ID: 22043041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
